10-Q: Abpro Holdings Reports Q3 2024 Results Amidst Merger Completion

Abpro Holdings, formerly Atlantic Coastal Acquisition Corp. II, released its Q3 2024 financial results, highlighting a net loss and the completion of its business combination with Abpro Corporation.

Summary

• Abpro Holdings, previously known as Atlantic Coastal Acquisition Corp. II, reported a net loss of $335,100 for the three months ended September 30, 2024, and a net loss of $1,722,675 for the nine months ended September 30, 2024.
• The company's operating and formation costs were $391,686 for the quarter and $1,926,428 for the nine-month period.
• Interest income from bank accounts and marketable securities held in the Trust Account partially offset these losses, totaling $84,240 for the quarter and $261,720 for the nine-month period.
• The company completed its business combination with Abpro Corporation on November 12, 2024, issuing approximately 50 million shares of common stock as merger consideration.
• Prior to the merger, approximately $3.75 million was removed from the trust account to pay redeeming shareholders at approximately $11.36 per share.
• The company also entered into a convertible promissory note for $3 million with YA II PN, LTD., receiving net proceeds of $2.755 million.
• As of September 30, 2024, the company had a working capital deficit of $7,480,594 and cash of $13,597 in its operating bank accounts.
• The company's future viability is largely dependent on its ability to raise additional capital, and there is substantial doubt about its ability to continue as a going concern within one year.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses, a working capital deficit, and substantial doubt about the company's ability to continue as a going concern. While the merger was completed, the overall outlook is negative due to the financial challenges and reliance on future capital raises.

Positives

• The business combination with Abpro Corporation was successfully completed.
• The company secured $2.755 million in net proceeds through a convertible promissory note.
• The company has a plan to address Nasdaq listing deficiencies.

Negatives

• The company reported a net loss of $335,100 for the quarter and $1,722,675 for the nine-month period.
• The company has a significant working capital deficit of $7,480,594.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed ineffective due to not filing timely tax returns and using trust account funds for operating purposes.

Risks

• The company's future viability is highly dependent on its ability to raise additional capital.
• There is no assurance that the company will be successful in obtaining additional financing.
• Failure to obtain funding could force the company to delay or eliminate research and development programs.
• The company's disclosure controls and procedures were deemed ineffective, which could affect the accuracy of financial reporting.
• The company is subject to potential penalties and interest due to unpaid excise tax obligations.

Future Outlook

The company's future viability is largely dependent on its ability to raise additional capital through equity and debt financings, collaboration agreements, and research grants. There is no assurance that the company will be successful in obtaining such additional financing.

Management Comments

• Management has determined the future viability of the Company is largely dependent on its ability to raise additional capital to finance its operations.
• Management has concluded there is substantial doubt as to the Company's ability to continue as a going concern within one year after the date the condensed consolidated financial statements are issued.

Industry Context

This announcement reflects the challenges faced by many SPACs in completing mergers and achieving profitability. The company's transition from a blank check company to an operating entity is a critical step, but it faces significant financial hurdles.

Comparison to Industry Standards

• The company's financial performance is below industry standards for biotech companies, particularly in terms of profitability and cash reserves.
• Many SPAC mergers have struggled to deliver value to shareholders, and Abpro Holdings faces similar challenges in integrating its operations and achieving growth.
• The company's reliance on external funding is a common trait among early-stage biotech companies, but the level of uncertainty about its ability to secure future financing is a concern.
• Compared to other SPACs, the high redemption rate and the need for additional capital raise raise concerns about the long term viability of the company.

Related Party Transactions

• The Sponsor has committed to advance the Company up to $1,750,000 to fund expenses related to investigating and selecting a target business and other working capital requirements.
• The Sponsor advanced the Company $2,270,051 as of September 30, 2024.
• The company issued non-interest bearing, unsecured promissory notes to the Sponsor totaling $160,000.
• The Sponsor received 600,601 shares of common stock in exchange for the extinguishment of $2,000,000 advances to ACAB.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and dependence on future capital raises.
• Employees may be affected by potential delays or reductions in research and development programs.
• Customers and suppliers may experience uncertainty due to the company's financial challenges.
• Creditors face increased risk due to the company's going concern issues.

Next Steps

• The company will focus on integrating the operations of Abpro Corporation.
• The company will seek additional funding through equity and debt financings, collaboration agreements, and research grants.
• The company will work to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

Merger, Business Combination, SPAC, Financial Results, Net Loss, Working Capital, Going Concern, Convertible Note, Redemption, Nasdaq, Abpro Holdings, Abpro Corporation